Daily Pharma News - 15 October 2026

NIPER Raebareli and AstraZeneca partner to expand clinical trial sites across India

A memorandum of understanding signed in New Delhi between NIPER Raebareli and AstraZeneca marks a significant step for India's clinical research ecosystem. With the Secretary of the Department of Pharmaceuticals present, the partnership will adopt, assess and mentor 25 clinical trial sites beyond the metropolitan hubs, building capability in ethics committee functioning, patient safety, and inspection readiness.

The initiative feeds directly into Biopharma SHAKTI's ambitious goal of building a network of 1,000 trial-ready sites across the country. For pharmacy students, this is a textbook example of how regulatory capacity-building works in practice: global pharma experience combined with public institutions to strengthen GCP compliance, ethics oversight and investigator training. Expect stronger clinical research career prospects in tier-2 and tier-3 cities as these emerging hubs come online.

CDSCO authorises Okogen's Treyegen (OKG-0303) Phase 1/2 EMERALD trial for conjunctivitis

The Central Drugs Standard Control Organisation (CDSCO) has cleared the EMERALD Phase 1/2 clinical trial of Treyegen (OKG-0303), Okogen's novel single ophthalmic therapy for acute infectious conjunctivitis. The product combines ranpirnase, tobramycin and oxymetazoline in one formulation, targeting both viral and bacterial causes of conjunctivitis - a notably common eye infection in India.

Fixed-dose ophthalmic combinations like this illustrate an important drug-development trend: addressing diagnostic uncertainty (viral versus bacterial) with a single broad-spectrum product. Pharmacy students should note the trial nomenclature - Phase 1/2 studies blend initial safety assessment with early efficacy signals - and watch how CDSCO's trial authorisation process mirrors global regulators when it comes to novel combination products.

Karnataka pharmacists demand updated State Pharmacy Council records

The Karnataka State Registered Pharmacists Organisation has urged the Food Safety and Drugs Administration to urgently update the State Pharmacy Council's records, pointing out that most official letters sent to registered pharmacists are returned because of incorrect addresses. The organisation has asked for mobile number and email verification of all registered pharmacists, along with official Pharmacy Inspector designations.

For pharmacy students in Karnataka and across South India, this story underlines why professional registration matters: council records are the backbone of licence renewals, employment verification and regulatory communication. Keeping your registration details current is not paperwork - it determines whether the regulator can reach you at all.

China's NMPA clears registrational Phase III of mesutoclax plus orelabrutinib in marginal zone lymphoma

China's National Medical Products Administration (NMPA) has cleared a registrational Phase III trial of InnoCare's mesutoclax, a novel oral BCL2 inhibitor, in combination with orelabrutinib for relapsed or refractory marginal zone lymphoma (MZL). This is the fifth registrational trial for the combination, which holds Breakthrough Therapy Designation and reported a 100% overall response rate at ASCO 2026.

The story is a strong learning case in modern oncology drug development: targeted combination therapy (BCL2 inhibition plus BTK inhibition), registrational trial design, and accelerated regulatory pathways. Students tracking global oncology pipelines will increasingly see Chinese sponsors like InnoCare leading late-stage haematology research alongside Western companies.

Russia registers Gleventra (givinostat) for Duchenne muscular dystrophy

Russia's Health Ministry has registered Gleventra (givinostat), developed by Promomed, as the country's first non-steroidal treatment for Duchenne muscular dystrophy. The drug's efficacy does not depend on the specific mutation type causing the disease, broadening the eligible patient population beyond mutation-specific therapies.

Givinostat is a histone deacetylase (HDAC) inhibitor, and its registration highlights the growing shift away from chronic corticosteroids in Duchenne management. For pharmacy students, this is a reminder that rare-disease drug development is increasingly active in non-Western markets, and that mechanism-based (rather than mutation-based) therapies can transform treatment access for genetic disorders.

FDA expands Anktiva indication in BCG-unresponsive bladder cancer

The US Food and Drug Administration (FDA) has approved an expanded indication for nogapendekin alfa inbakicept-pmln (Anktiva) in combination with BCG for BCG-unresponsive non-muscle invasive bladder cancer. The approval extends the earlier carcinoma in situ indication to include high-grade papillary-only tumours.

This is a classic example of indication expansion - a regulatory pathway pharmacy students must understand. An IL-15 superagonist combined with the traditional BCG immunotherapy, Anktiva's story shows how immunotherapy combinations are reshaping even well-established treatment areas, and how real-world evidence and follow-on trials drive label growth after first approval.

Conclusion

Today's news spans the full breadth of modern pharmacy practice. India's push to decentralise clinical trials and Karnataka's call for better pharmacist records show regulation evolving at home; CDSCO's Treyegen trial clearance brings a promising eye-care innovation closer; China's registrational oncology trial, Russia's first non-steroidal Duchenne drug, and the FDA's Anktiva expansion show global drug development moving fast across rare diseases, oncology and immunotherapy. For pharmacy students, the takeaway is clear: regulatory awareness - from ethics committees to indication expansion - is as career-critical as pharmacology itself. Keep following the regulators, and you will stay ahead of the medicines of tomorrow.

References

← All daily news